DBV Technologies S.A. — Regulatory Filings 2020

Jan 9, 2020

6-K 1 d824406d6k.htm 6-K 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of January 2020

Commission File Number: 001-36697

DBV TECHNOLOGIES S.A.

(Translation of registrant’s name into English)

177-181 avenue Pierre Brossolette

92120 Montrouge France

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXPLANATORY NOTE

On January 8, 2020, DBV Technologies S.A. announced positive topline results of the three-year, open-label extension of the Phase III PEPITES trial, or PEOPLE trial, evaluating the long-term efficacy and safety of investigational Viaskin Peanut in peanut-allergic children ages 4 to 11 years. DBV Technologies S.A. prepared a presentation in connection with the topline results of the PEOPLE trial, which it intends to use in conferences and meetings with investors. Copies of the press release and the presentation are filed with this Report of Foreign Private Issuer on Form 6-K as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.

EXHIBIT LIST

Exhibit	Description
99.1	Press Release dated January 8, 2020.
99.2	Presentation of DBV Technologies S.A. dated January 8, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

DBV TECHNOLOGIES S.A. — By:	/s/ Daniel Tassé
Name:	Daniel Tassé
Title:	Chief Executive Officer